TED Ted Baker Plc

RNS Number:3876O
ABCAM Plc
21 December 2006


For immediate release                                          21 December 2006





                                   ABCAM PLC

                           ("Abcam" or "the Company")





     International Distribution Agreement Signed with Tepnel Life Sciences



Abcam plc (AIM: ABC), the rapidly growing company that markets antibodies via an
online catalogue, is pleased to announce that it has signed a global licensing
agreement with Tepnel Life Sciences PLC ("Tepnel") (AIM: TED), the UK-based
international molecular diagnostics and research products & services group, for
the distribution of Tepnel's Diaclone range of diagnostic and research products.



The Diaclone range includes more than 350 immunological products designed for
therapy, diagnostic and research applications.  The distribution partnership
with Tepnel is an exclusive agreement for sales in Japan, Canada, and South
America.  In the USA Abcam will share the sales rights for the Diaclone range
with Tepnel.  The sales arrangement is non-exclusive elsewhere in the world.



As part of the agreement Abcam will give Tepnel an upfront payment and has
guaranteed to a minimum level of annual sales.





Commenting on the announcement, Jonathan Milner, Abcam's Chief Executive
Officer, said: "We are excited about this agreement with Tepnel where we have
worldwide sales rights to a wide range of products.  This opportunity allows
Abcam to expand its product range into antibody related products and gives us an
opportunity to sell more products across a wide geographical footprint."



Dr Allan Brown, Managing Director of Tepnel Research Products & Services,
commented: "The agreement with Abcam is a significant one for Tepnel as our
Diaclone product range is already one of the world's leading sources of
immunological products and with our new partnership, we will be able to further
extend our market share.  As the number one player in this market, Abcam
possesses the awareness, reputation and know-how to help attain the market
potential for Diaclone products."



                                     -End-





For further information please contact:


Abcam plc                                                  + 44 (0) 1223 696000

Jonathan Milner, Chief Executive Officer

Eddie Powell, Chief Financial Officer

www.abcam.com



Buchanan Communications on behalf of Abcam                 + 44 (0) 20 7466 5000

Mary-Jane Johnson



Tepnel Life Sciences plc                                   +44 (0 )161 946 2200

Allan Brown, Managing Director, Tepnel Research Products &
Services




De Facto Communications on behalf of Tepnel                +44 (0)20 7861 3838

Richard Anderson







Notes for editors



About Abcam plc



Abcam is a producer and distributor of research-grade antibodies headquartered
in Cambridge, UK, with a US office located in Cambridge, Massachusetts. Abcam
was admitted to AIM in November 2005 and trades under the ticker symbol ABC.
The Company produces and distributes its own and third party produced antibodies
to academic and commercial users throughout the world with product information
provided and ordering available through the Company's website, www.Abcam.com.
The antibodies are sold almost entirely under the Abcam brand name. The
Company's vision is to build the largest online antibody resource in the world
while also ensuring that the antibodies are of high quality and commercially
viable. Abcam now has an online catalogue of 25,000 products, most of which are
antibodies, from over 200 suppliers supported by up-to-date and detailed
technical data sheets, which are created by the Company. The Company currently
employs 100 staff.





About Tepnel Life Sciences plc



Tepnel Life Sciences (AIM:TED) is a UK-based international life sciences
products and services group with two main divisions, Molecular Diagnostics and
Research Products & Services. The Company has laboratories, manufacturing and
operations in the USA, UK and France with 195 employees.  TLS provides test
kits, reagents and services to two highly synergistic markets, these being
Molecular Diagnostics and Biomedical Research.  The company's strategy has been
to identify high growth niche opportunities within these multi-billion pound
markets.  TLS focuses on these niche opportunities with internally developed
products, patents, expertise and know-how as well as strategic acquisitions, to
develop a leadership position within these defined market segments.





About antibodies



Antibodies are proteins produced by white blood cells in response to the
introduction of a foreign body known as an antigen. Antibodies, which have a
wide variety of uses in research, diagnostics and therapeutics, are used by
bioscientists in research into disease and into the human genome, where they are
used to mark and identify specific cells and other living matter. The number of
human antibodies of use in research is potentially greater than one million.




                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

AGRTMBRTMMITBBF

Ted Baker (LSE:TED)
Historical Stock Chart
From Jun 2024 to Jul 2024

Ted Baker (LSE:TED)
Historical Stock Chart
From Jul 2023 to Jul 2024